Insider transactions involving Exelixis, Inc. (NASDAQ:EXEL) Senior Vice President and General Counsel Brenda Hefti have drawn attention following sales of the company's common stock reported on May 15 and May 18, 2026. The total value of shares sold by Ms. Hefti reached $332,641 across two dates, with additional dispositions occurring to cover tax obligations related to vested equity.
On May 18, Ms. Hefti executed a sale of 6,625 shares of Exelixis common stock. This transaction generated total proceeds valued at $332,641. The selling price varied across the sales period, ranging from $49.84 to $50.51 per share, resulting in a weighted average sale price of $50.21 per share. These dispositions were managed under the framework of a Rule 10b5-1 trading plan that Ms. Hefti had initially adopted on November 19, 2025.
A separate transaction took place on May 15, when Ms. Hefti disposed of 6,411 shares of common stock at a fixed price of $51.10 per share, totaling $327,602. Crucially, these specific shares were withheld by Exelixis to satisfy outstanding tax liabilities. These taxes stemmed from the vesting of restricted stock units (RSUs) awarded on several dates: March 4, 2022; February 29, 2024; and February 26, 2025.
Following these reported sales and withholdings, Ms. Hefti maintains a direct holding of 106,762 shares of Exelixis common stock. This total ownership figure is comprehensive, encompassing not only current holdings but also shares anticipated to vest upon the fulfillment of restricted stock units, awards based on performance metrics, and additional shares acquired through participation in the company’s 2000 Employee Stock Purchase Plan. Furthermore, Ms. Hefti holds an indirect stake totaling 5,527 shares via the Exelixis, Inc. 401(k) Plan.
Beyond the details of executive trading, recent corporate news from Exelixis provides significant context for the company's valuation and strategic direction. The firm reported robust financial results for the first quarter of 2026. These results surpassed market expectations in both revenue generation and earnings per share (EPS).
Specifically, the company announced an EPS of $0.87 per share. This figure exceeded the forecasted amount of $0.77, representing a substantial positive surprise of 12.99%. In terms of top-line growth, quarterly revenue reached $611 million. This was slightly higher than the anticipated revenue of $608.95 million.
Furthermore, Exelixis has solidified its position in clinical research through a major collaboration agreement with Merck. The partnership focuses on conducting a phase 3 trial for patients diagnosed with resected stage II/III colorectal cancer. Under the terms of this joint effort, Exelixis will take the lead role by sponsoring the STELLAR-316 pivotal trial. In parallel, Merck is contributing its subcutaneous anti-PD-1 therapy, known as KEYTRUDA QLEX.
The combination of strong financial performance and strategic clinical partnerships underscores Exelixis’s ongoing efforts toward both financial expansion and advanced scientific development in the healthcare sector. The company's stock currently trades near its 52-week high of $51.63, reflecting a current valuation of $12.25 billion.
Risks
- Executive selling activity, even when structured through a Rule 10b5-1 plan, may suggest internal valuation concerns.
- Reliance on the successful completion of the STELLAR-316 phase 3 trial and the continued effectiveness of the collaboration with Merck.
- The stock's current high valuation relative to historical trading ranges.
More from Insider Trading
Risks
- Executive selling activity, even when structured through a Rule 10b5-1 plan, may suggest internal valuation concerns.
- Reliance on the successful completion of the STELLAR-316 phase 3 trial and the continued effectiveness of the collaboration with Merck.
- The stock's current high valuation relative to historical trading ranges.